Cancer Biopsy Market Size, Share & Analysis Report, 2023-2032
The global Cancer Biopsy market size was estimated at USD 25.6 billion in 2022 and is expected to surpass around USD 135.24 billion by 2032 and poised to grow at a compound annual growth rate (CAGR) of 18.11% during the forecast period 2023 to 2032.
Key Pointers:
Cancer Biopsy Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 30.24 Billion |
| Market Size by 2032 | USD 135.24 Billion |
| Growth Rate From 2023 to 2032 | CAGR of 18.11% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | Type, Product, Application |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
| Key Companies Profiled | QIAGEN; Illumina Inc.; ANGLE plc.; BD; Myriad Genetics; Hologic, Inc.; BIOCEPT, INC.; Thermo Fisher Scientific, Inc.; Danaher Corporation; F. Hoffmann-La Roche Ltd.; Epigenomics AG; HelioHealth (Laboratory for Advanced Medicine); 20/20 Genesystems, Inc. (Genesys Biolabs); Personal Genome Diagnostics, Inc.; Natera, Inc.; Chronix Biomedical, Inc.; Personalis, Inc.; Lucence Health, Inc.; Freenome Holdings, Inc.; Grail, INC.; Guardant Health; Exact Sciences Corporation; Biodesix (Integrated Diagnostics); Oncimmune |
The increasing prevalence of oncology indications, coupled with the growing geriatric population, is a major factor expected to fuel market growth. In addition, the advent of liquid biopsy and the ongoing developments in biopsy techniques are expected to propel the growth of the market. Various techniques including endoscopic, bone marrow, skin, needle, and surgical biopsies are incorporated in the oncology diagnostics field. Amongst these techniques, needle biopsies are considered a preferred technique aimed at the early detection of patients. However, advantages of fine-needle aspiration (FNA) type needle biopsies such as less invasion along with lesser time for the outcomes have supplemented the market growth.
Additionally, series of advancements in image-guided biopsies and expanding applications of the same has been marked as key trends in recent years. For instance, in 2017, magnetic resonance imaging targeted biopsies were evaluated for their potential in prostate tumor detection. The study concluded that multi-parametric magnetic resonance (MR) imaging-based biopsies helped in minimizing false-negative results, further enhancing risk assessment.
This test confirms tumor presence via the identification of genetic markers in the blood. This technique is gaining immense popularity since its inception and this is attributed to the benefits associated with it such as cost-effectiveness, lesser complexity and time consumption, and minimal pain during the biopsy. Additionally, various companies operating in data analysis and diagnostics are entering this market.
The emergence of liquid biopsy for cancer diagnosis, screening, prognosis, and treatment monitoring has significantly enhanced the competition and capabilities in this market. Operating entities are undertaking strategic initiatives to enter this arena and are engaged in conducting liquid biopsies, which is expected to fuel the growth of the market within clinical settings. Currently, liquid biopsy is used in patients who cannot undergo a tissue biopsy for advanced, metastatic cancer diagnosis.
Type Insights
Tissue biopsy accounted for the largest revenue share of over 84.0% in 2022. It is still considered to be a mainstay of biopsies and is largely adopted across various cancer diagnosis applications. This is attributed to robust research activities evaluating its safety and efficacy, which has contributed to this segment growth.
Advancements targeted towards enhancing tissue biopsy procedures are expected to maintain the lead of the tissue biopsy segment for the next few years. For instance, Cernostics is developing an assay suitable for diagnosing cancer patients suffering from Barrett's Esophagus. This one-of-a-kind diagnostic test makes use of biopsy images that are digitally scanned, which aids in the analysis and quantification of alterations occurring at the cellular or molecular levels within a tissue.
The rising preference for liquid biopsy among physicians has been observed in recent years, which is supplemented by its ability to offer disease snapshots from the primary and distant tumor sites. This approach is put to use in personalized medicine treatment, wherein tumor markers are sampled repeatedly to alter the therapy based on the patient’s response to the treatment.
Application Insights
Breast biopsy held the largest share of over 18.6% in 2022. Breast cancer has the largest prevalence rate. Around 1 in 8 U.S. women develop invasive breast cancer as per the U.S. breast cancer statistics. An estimated 276,480 new cases of invasive breast cancer were diagnosed in women in 2020in the U.S., along with more than 40,000 new cases of non-invasive breast cancer.
The rising number of patients suspected of having breast cancer is subjected to microscopic analysis of breast tissue, which is mandatory to obtain a definitive diagnosis, along with detecting the stage and characterization of type. This has propelled the demand for a needle biopsy or surgical biopsy to obtain tissue for microscopic analysis, in turn contributing to the segment growth.
Circulating tumor cells (CTC)-based liquid biopsies have the ability to track the minimal residual disease (MRD) in non-metastatic prostate cancer patients, along with the follow-up evaluations performed to offer independent prognostic insights. A novel European project, Transcan-PROLIPSY is designed to assess the potential of combined use of CTCs, exosomes, and ctDNA as a noninvasive liquid biopsy modality to diagnose prostate cancer followed by its routine evaluation.
Product Insights
Kits and consumables accounted for the largest revenue share of over 64.0% in 2022 as these are integral across various stages of biopsies. Moreover, robust investments by key players operating in this industry have made significant contributions to the segment growth. The segment growth can also be attributed to a considerable increase in the number of patients across the globe that demand instruments and kits to be efficient, accurate, and rapid.
Cancer biopsy has witnessed several developments in terms of instruments, kits, and consumables. With liquid biopsy emerging as a multimodal tool of diagnosis in the field of clinical oncology, the development of efficient products associated with biopsies is pivotal. Though the existing instruments are used predominantly, they are accompanied by various shortcomings. However, the advent of novel technologies is expected to increase the demand for instruments significantly in the coming years.
Several emerging manufacturers are focusing on launching instruments that are able to enhance endoscopy-based biopsies. For instance, BiBBInstruments AB, a Swedish company, has established a strong presence in the instruments market space under the brand – EndoDrill.
Regional Insights
North America accounted for the largest share of over 44.6%in 2022. The region is anticipated to maintain its lead throughout the forecast period, with the U.S. making significant contributions to the regional revenue. In addition, distributors and manufacturers operating in this region aim to distribute and develop novel kits that are well-suited for rapid diagnostic applications.
Moreover, the increasing adoption of liquid biopsies across the U.S. is largely favored by the profitable strategies laid out by the respective government authorities. Regulatory strategies for liquid biopsy-based oncology diagnostics rely on the framework, which has been developed in recent years by the U.S. Food and Drug Administration (FDA). This framework consists of the guidelines associated with enrichment biomarkers and companion diagnostics, and approval precedents. The ultimate success of liquid biopsy regulatory pathways has been supplemented by the incremental value of FDA approval for Clinical Laboratory Improvement Amendment (CLIA)â€developed tests.
Some of the prominent players in the Cancer Biopsy Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Cancer Biopsy market.
By Product
By Type
By Application
By Region
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Cancer Biopsy Market
5.1. COVID-19 Landscape: Cancer Biopsy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Cancer Biopsy Market, By Product
8.1. Cancer Biopsy Market, by Product Type, 2023-2032
8.1.1. Instruments
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Kits and Consumables
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Services
8.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Cancer Biopsy Market, By Application
9.1. Cancer Biopsy Market, by Application, 2023-2032
9.1.1. Breast Cancer
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Colorectal Cancer
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Cervical Cancer
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Lung Cancer
9.1.4.1. Market Revenue and Forecast (2020-2032)
9.1.5. Prostate Cancer
9.1.5.1. Market Revenue and Forecast (2020-2032)
9.1.6. Skin Cancer
9.1.6.1. Market Revenue and Forecast (2020-2032)
9.1.7. Blood Cancer
9.1.7.1. Market Revenue and Forecast (2020-2032)
9.1.8. Kidney Cancer
9.1.8.1. Market Revenue and Forecast (2020-2032)
9.1.9. Liver Cancer
9.1.9.1. Market Revenue and Forecast (2020-2032)
9.1.10. Pancreatic Cancer
9.1.10.1. Market Revenue and Forecast (2020-2032)
9.1.11. Ovarian Cancer
9.1.11.1. Market Revenue and Forecast (2020-2032)
9.1.12. Others
9.1.12.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Cancer Biopsy Market, By Type
10.1. Cancer Biopsy Market, by Type, 2023-2032
10.1.1. Tissue Biopsies (Fine Needle Aspiration (FNA), Core Needle Biopsy (CNB))
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Liquid Biopsies
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Others
10.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Cancer Biopsy Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Product (2020-2032)
11.1.2. Market Revenue and Forecast, by Application (2020-2032)
11.1.3. Market Revenue and Forecast, by Type (2020-2032)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Product (2020-2032)
11.1.4.2. Market Revenue and Forecast, by Application (2020-2032)
11.1.4.3. Market Revenue and Forecast, by Type (2020-2032)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Product (2020-2032)
11.1.5.2. Market Revenue and Forecast, by Application (2020-2032)
11.1.5.3. Market Revenue and Forecast, by Type (2020-2032)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Product (2020-2032)
11.2.2. Market Revenue and Forecast, by Application (2020-2032)
11.2.3. Market Revenue and Forecast, by Type (2020-2032)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Product (2020-2032)
11.2.4.2. Market Revenue and Forecast, by Application (2020-2032)
11.2.4.3. Market Revenue and Forecast, by Type (2020-2032)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Product (2020-2032)
11.2.5.2. Market Revenue and Forecast, by Application (2020-2032)
11.2.5.3. Market Revenue and Forecast, by Type (2020-2032)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Product (2020-2032)
11.2.6.2. Market Revenue and Forecast, by Application (2020-2032)
11.2.6.3. Market Revenue and Forecast, by Type (2020-2032)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Product (2020-2032)
11.2.7.2. Market Revenue and Forecast, by Application (2020-2032)
11.2.7.3. Market Revenue and Forecast, by Type (2020-2032)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Product (2020-2032)
11.3.2. Market Revenue and Forecast, by Application (2020-2032)
11.3.3. Market Revenue and Forecast, by Type (2020-2032)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Product (2020-2032)
11.3.4.2. Market Revenue and Forecast, by Application (2020-2032)
11.3.4.3. Market Revenue and Forecast, by Type (2020-2032)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Product (2020-2032)
11.3.5.2. Market Revenue and Forecast, by Application (2020-2032)
11.3.5.3. Market Revenue and Forecast, by Type (2020-2032)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Product (2020-2032)
11.3.6.2. Market Revenue and Forecast, by Application (2020-2032)
11.3.6.3. Market Revenue and Forecast, by Type (2020-2032)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Product (2020-2032)
11.3.7.2. Market Revenue and Forecast, by Application (2020-2032)
11.3.7.3. Market Revenue and Forecast, by Type (2020-2032)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Product (2020-2032)
11.4.2. Market Revenue and Forecast, by Application (2020-2032)
11.4.3. Market Revenue and Forecast, by Type (2020-2032)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Product (2020-2032)
11.4.4.2. Market Revenue and Forecast, by Application (2020-2032)
11.4.4.3. Market Revenue and Forecast, by Type (2020-2032)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Product (2020-2032)
11.4.5.2. Market Revenue and Forecast, by Application (2020-2032)
11.4.5.3. Market Revenue and Forecast, by Type (2020-2032)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Product (2020-2032)
11.4.6.2. Market Revenue and Forecast, by Application (2020-2032)
11.4.6.3. Market Revenue and Forecast, by Type (2020-2032)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Product (2020-2032)
11.4.7.2. Market Revenue and Forecast, by Application (2020-2032)
11.4.7.3. Market Revenue and Forecast, by Type (2020-2032)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Product (2020-2032)
11.5.2. Market Revenue and Forecast, by Application (2020-2032)
11.5.3. Market Revenue and Forecast, by Type (2020-2032)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Product (2020-2032)
11.5.4.2. Market Revenue and Forecast, by Application (2020-2032)
11.5.4.3. Market Revenue and Forecast, by Type (2020-2032)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Product (2020-2032)
11.5.5.2. Market Revenue and Forecast, by Application (2020-2032)
11.5.5.3. Market Revenue and Forecast, by Type (2020-2032)
Chapter 12. Company Profiles
12.1. Myriad Genetics Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Guardant Health Inc.
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Exact Sciences Corporation
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Bio-Rad Laboratories Inc.
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Agena Bioscience Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Personal Genome Diagnostics Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Exosome Diagnostics Inc.
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. ANGLE Plc.
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. F. Hoffmann-La Roche Ltd.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers